logo-loader

VentriPoint Diagnostics brings in over C$1mln from placing; closes second tranche

Last updated: 15:16 14 Sep 2018 BST, First published: 10:16 14 Sep 2018 BST

1536934697_MedicalMonitor
VentriPoint has developed a suite of applications for all major heart diseases and imaging modalities

Heart-imaging specialist VentriPoint Diagnostics Ltd (CVE:VPT) has closed the second and final tranche of its previously announced placing, raising more than C$511,000.

The group issued around 2.43mln units at C$0.21 each for gross proceeds of $511,499.94. In total, the firm raised gross proceeds of C$1,011,499.94 under the placing.

Proceeds will be used for sales and marketing, development and general working capital, Ventripoint said. Each unit consists of one Ventripoint share, and one-half of a share warrant. Each whole warrant will entitle the bearer to buy one further share at US$0.34 each for two years after the issue.

Chief executive Dr George Adams subscribed for 1.5mln units, the company said in the regulatory filing.

'We have a shot at being a multi-billion dollar company', says VentriPoint...

Dr George Adams, CEO & president of VentriPoint Diagnostics (CVE:VPT) runs Proactive through the company's heart analysis technology and growth strategy as well as plans for 2017.

on 20/3/17